ORKA
Oruka Therapeutics, Inc.·Healthcare
59.58
6.321%(−4.02)
Market ClosedLast Updated: — ET
52W L: $7.6252W H: $64.61
ORKA NEWS
defenseworld.net
5d ago
Secure Asset Management LLC Takes Position in Oruka Therapeutics, Inc. $ORKA
Secure Asset Management LLC purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 81,664 shares of the company's stock, valued at approximately $2,475,000. Secure Asset Management LLC owned approximately 0.17% of
defenseworld.net
Mar 22
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12
zacks.com
Mar 17
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Oruka Therapeutics, Inc. (ORKA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
defenseworld.net
Mar 14
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA
Avoro Capital Advisors LLC purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,333,340 shares of the company's stock, valued at approximately $25,640,000. Oruka Therapeutics accounts for about 0.3% of Avoro Capital Advisors LLC's
defenseworld.net
Mar 14
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High After Better-Than-Expected Earnings
Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report) reached a new 52-week high during mid-day trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $38.75 and last traded at $38.6030, with a volume of 220537 shares. The stock had previously closed at $31.99. The company reported
globenewswire.com
Mar 12
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026
